Literature DB >> 19438733

Rejection and acceptance of possible side effects of migraine prophylactic drugs.

Pedro A Kowacs1, Elcio J Piovesan, Stewart J Tepper.   

Abstract

INTRODUCTION: Successful prophylactic therapy might require not only efficacy but meeting patients' expectations about the potential side effects of the preventative drug selected. Prior to prescribing prophylactic drugs to prophylaxis-naive migraine patients, we aimed to quantify the acceptance or rejection of some of the possible adverse events associated with migraine prophylactic drugs.
METHODS: A total of 203 prophylactic-naive migraine/chronic migraine patients, 17 (8.4%) male, 186 (91.6%) female, aged 19 to 65 years were serially selected and asked to answer bidirectional visual numerical scales designed for this purpose, with 1 scale for each side effect. The question posed was: "How much would you accept or reject the following side effects to get rid of your migraine headaches?" The side effects listed were dry mouth, epigastric burning, low energy, tingling, somnolence, depression, tremor, insomnia, memory loss, sluggishness, weight gain, and weight loss.
RESULTS: The most rejected possible side effects were weight gain, memory loss, and depression. Weight loss was better accepted by patients with a higher body mass. In general, there was a higher acceptance of side effects for patients taking more than 10 symptomatic medications a month, especially for loss of energy and somnolence. Older patients lacked an acceptance of tremor.
CONCLUSION: Our findings reinforce and quantify findings similar to those in the literature, and provide new data regarding the preference determinants for prophylactic medication.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19438733     DOI: 10.1111/j.1526-4610.2009.01431.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  13 in total

Review 1.  CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine.

Authors:  Heike Israel; Lars Neeb; Uwe Reuter
Journal:  Curr Pain Headache Rep       Date:  2018-04-06

Review 2.  Behavioral Weight Loss Treatments for Individuals with Migraine and Obesity.

Authors:  Cynthia Cervoni; Dale S Bond; Elizabeth K Seng
Journal:  Curr Pain Headache Rep       Date:  2016-02

Review 3.  Exercise in Treatment of Migraine Including Chronic Migraine.

Authors:  Tae-Jin Song; Min Kyung Chu
Journal:  Curr Pain Headache Rep       Date:  2021-02-25

4.  Efficacy of Modified Wuzhuyu Decoction Granule ( ) for Migraine Patients with Cold and Stasis Obstructing Meridian Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Hong-Wei Liu; Yi-Huai Zou; Ke-Gang Cao; Li-Hua Yu; Yong Zhang; Cai-Hong Fu; Da-Yong Ma
Journal:  Chin J Integr Med       Date:  2017-07-25       Impact factor: 1.978

5.  Prophylactic treatment of migraine by GPs: a qualitative study.

Authors:  Frans Dekker; Arie Knuistingh Neven; Boukje Andriesse; David Kernick; Michel D Ferrari; Willem J J Assendelft
Journal:  Br J Gen Pract       Date:  2012-04       Impact factor: 5.386

Review 6.  Obesity and Migraine in Childhood.

Authors:  Tal Eidlitz Markus; Irene Toldo
Journal:  Curr Pain Headache Rep       Date:  2018-05-03

Review 7.  Obesity and headache: Part II--potential mechanism and treatment considerations.

Authors:  Nu Cindy Chai; Dale S Bond; Abhay Moghekar; Ann I Scher; B Lee Peterlin
Journal:  Headache       Date:  2014-02-11       Impact factor: 5.887

Review 8.  Headache and obesity in the pediatric population.

Authors:  Christopher B Oakley; Ann I Scher; Ana Recober; B Lee Peterlin
Journal:  Curr Pain Headache Rep       Date:  2014-05

9.  Prophylactic treatment of migraine; the patient's view, a qualitative study.

Authors:  Frans Dekker; Arie Knuistingh Neven; Boukje Andriesse; David Kernick; Ria Reis; Michel D Ferrari; Willem J J Assendelft
Journal:  BMC Fam Pract       Date:  2012-03-09       Impact factor: 2.497

10.  Metabolic syndrome and migraine.

Authors:  Amit Sachdev; Michael J Marmura
Journal:  Front Neurol       Date:  2012-11-19       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.